PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsPseudomonas infections
MeSH D011552 - pseudomonas infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016905:Gram-negative bacterial infections
29 Companies
15 Drugs
$
Success rate
D011552: 
Pseudomonas infections
128 Companies
46 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCiprofloxacin Ciprofloxacin  2004-06-09   
Tobramycin Tobramycin  1992-01-30   
Colistimethate Colobreathe  2012-02-13   
PadagisDexamethasone, Tobramycin Tobramycin Dexamethasone  2022-02-11   
Taro PharmaceuticalCiprofloxacin Ciprofloxacin  2004-10-06   
NATCO PharmaCiprofloxacin Ciprofloxacin  2004-06-09   
MylanTobramycin Tobramycin  2008-03-11   
ViatrisTobramycin Tobi  1997-12-22   
GSKCeftazidime Ceptaz  1990-09-27   
Ceftazidime Pentacef  1995-11-07   
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
0%
0/6
Phase 2
0%
0/1
Phase 3
97%
31/32
Approved: 27Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Moxifloxacin
Mylan
Moxifloxacin,
Tobramycin
Johnson & Johnson
Levofloxacin
GSK
Ceftazidime,
Clavulanate,
Neomycin,
Ticarcillin,
Sodium chloride,
Colimycin
Roche
Ceftriaxone
Novartis
Dexamethasone,
Tobramycin,
Aspartame
Harrow
Moxifloxacin
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use